The companion animal pharmaceuticals market is expected to register significant growth between 2017 and 2022. The key factors responsible for the growth of this market are increasing population of companion animals, rising pet ownership, growing animal healthcare expenditure, rising awareness about zoonotic diseases, and growing concern about pet health and wellbeing. Growing consolidation of the animal health industry is a major trend in the global companion animal pharmaceuticals market.
In this report, the global companion animal pharmaceuticals market is segmented by indication, animal type, distribution channel, and region. Based on indication, this market is further segmented into infectious diseases, dermatological diseases, orthopedic diseases, behavioral diseases, pain, dental diseases, and others. In 2016, the pharmaceuticals used to treat infectious diseases held the largest share of the market. This large share is mainly attributed to increasing adoption of anti-infective drugs such as antibiotics, antimicrobials, and parasiticides (especially endectocides) to treat infectious diseases in companion animals. On the basis of animal type, the market is categorized into dogs, cats, horses, and other companion animals. Pharmaceuticals used for treating dogs accounted for the largest share of the market in 2016. Based on the distribution channel, the market is categorized into veterinary hospitals, veterinary clinics, and retail pharmacies.
North America is the largest regional segment of the market. The markets in Asia-Pacific and Latin America are expected to register the highest growth during the forecast period, primarily due to rising pet ownership, growing disposable income, and increasing awareness about animal health.
Some of the major players competing in this market are Zoetis, Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Vetoquinol (France), Virbac (France), Dechra Pharmaceuticals plc (U.K.), Ceva Sante Animale (France), and Aratana Therapeutics, Inc. (U.S.).
Scope of the Report:
The research report categorizes the global companion animal pharmaceuticals market into the following segments and subsegments:
Global Companion Animal Pharmaceuticals Market, by Indication
Global Companion Animal Pharmaceuticals Market, by Animal Type
Global Companion Animal Pharmaceuticals Market, by Distribution Channel
Global Companion Animal Pharmaceuticals Market, by Region
Table of Contents
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
2 Research Methodology
2.1 Research Approach
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Dynamics
6 Global Companion Animal Pharmaceuticals Market, By Indication
6.2 Infectious Diseases
6.2.1 Antibiotics and Antimicrobials
6.3 Dermatologic Diseases (Skin Diseases)
6.4 Orthopedic Diseases
6.5 Behavioral Disorders
6.7 Dental Diseases
7 Global Companion Animal Pharmaceuticals Market, By Animal Type
7.5 Other Companion Animals
8 Global Companion Animal Pharmaceuticals Market, By Distribution Channel
8.2 Veterinary Hospitals
8.3 Veterinary Clinics
8.4 Retail Pharmacies
9 Global Companion Animal Pharmaceuticals Market, By Region
9.2 North America
9.3.6 Rest of Europe (RoE)
9.4 Asia Pacific (APAC)
9.4.4 Rest of Asia Pacific (RoAPAC)
9.5 Latin America
9.6 Middle East and Africa
10 Competitive Landscape
10.2 Vendor Dive Overview
10.3 Competitve Benchmarking
10.3.1 Product Portfolio Assesment
10.3.2 Business Strategies Analysis
11 Company Profiles*
(Business Overview, Key Financials, Company Scorecard, Recent Developments)
11.1 Zoetis, Inc.
11.2 Bayer AG
11.3 Boehringer Ingelheim GmbH
11.4 Eli Lilly and Company
11.5 Merck & Co., Inc.
11.8 Dechra Pharmaceuticals PLC
11.9 Ceva Sante Animale
11.10 Aratana Therapeutics, Inc.
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Available Customizations
12.4 Introducing RT: Real Time Market Intelligence
12.5 Related Reports
*The List of Companies Mentioned Above is Indicative Only and Might Change During the Course of the Study.
*Details on Key Financials Might Not Be Captured in Case of Unlisted Companies.
Benchmarking the rapid strategy shifts of the Top 100 companies in the Companion Animal Pharmaceuticals MarketRequest For Special Pricing